海王生物：预计2025年亏损4.9亿元至6亿元，优化业务结构布局导致短期业绩受影响

Core Viewpoint - Haiwang Biological (000078) expects a net profit loss attributable to shareholders of approximately 490 million to 600 million yuan for the fiscal year 2025, representing an increase in loss of 49.72% to 58.94% compared to the previous year's loss of 1.193 billion yuan [1] Group 1: Financial Performance - The main reason for the performance change is the optimization of business structure, which is expected to impact net profit loss by approximately 110 million to 150 million yuan [1] - The company anticipates goodwill impairment of about 120 million to 150 million yuan, with the scale of impairment significantly reduced compared to previous years [1] - Expected credit impairment losses are estimated to be between 150 million to 220 million yuan, indicating a generally good credit foundation, although some public medical institutions face long-term debt recovery issues [1]